TW202114625A - Cosmetic tool - Google Patents

Abstract

The purpose of the present invention is to provide a cosmetic tool which can be used for a long period of time such as when sleeping and has excellent antiseptic properties. This cosmetic tool 1 includes: a cosmetic tool body 11 having a contact surface 11a capable of contacting at least a part of the face; and a chemical agent applied to the contact surface 11a in an application amount of 20-150 g/m2, wherein the chemical agent contains at least one among silver oxide and iodopropynyl butylcarbamate, and trihydric alcohol.

Description

cosmetic products

The present invention relates to a cosmetic product.

As a beauty product used in contact with skin such as a face, for example, a bag or a mask impregnated with a drug containing cosmetic ingredients such as a moisturizer or the like can be cited. In order for such beauty products to further exert the beauty effect of the drug contacted, the use time may be required to be used for a long time, specifically, to be used for a long time such as bedtime. Specific examples of such beauty products include masks described in Patent Document 1 and the like.

Patent Document 1 describes a mask including: a mask body having a shape covering at least the mouth and nostrils; a pair of holding parts connected to the side parts of the mask body in a state covering the mouth and nostrils, and connecting the mask body The mask body is maintained in a state in which the mask body covers the mouth and nostrils; and the medicine layer is provided on the inside of the mask body and contains medicine, and the coating amount of the medicine on the inner surface of the mask body is 20 g/m ² or more. According to Patent Document 1, it is disclosed that it is possible to provide a mask that can prevent the drug from adhering to the quilt while the mask is in bed, and can obtain a facial beauty effect with the feeling of use such as a cosmetic mask. In addition, Patent Document 1 discloses that the coating amount of the drug is preferably 150 g/m ² or less, so that the drug can be prevented from adhering to the quilt during bedtime and ease of breathing can be ensured. [Prior Art Document] [Patent Document]

[Patent Document 1] Japanese Patent Laid-Open No. 2019-10377

[The problem to be solved by the invention] When a cosmetic product impregnated with a medicine as described in Patent Document 1 is used in contact with the face, not only the cosmetic effect, such as moisture retention, but also antiseptic properties by the contacted medicine are required. In particular, as in beauty products used for a long period of time such as bedtime, when the coating amount of the drug is relatively small, antiseptic properties are more required.

The present invention was made in view of the above-mentioned circumstances, and its object is to provide a beauty product that can be used for a long time such as bedtime and has excellent antiseptic properties. [Means to solve the problem]

The inventors of the present invention conducted various studies, and as a result, found that the above-mentioned object can be achieved by the following present invention.

One aspect of the beauty product of the present invention is the following beauty product, which is characterized by comprising: a beauty product body having a contact surface capable of contacting at least a part of the face; and a medicament at a rate of 20 g/m ² ～150 g/ The coating amount of m ² is coated on the contact surface, and the agent includes at least one of silver oxide and propynyl iodide of butyl carbamate, and triol.

According to this configuration, first, since the drug is applied to the contact surface that can come into contact with the face, that is, the inner surface of the beauty product body, it is possible to prevent the drug from adhering to bedding such as quilts during bedtime. Furthermore, since the coating amount of the drug is small and is 150 g/m ² or less, it is also possible to prevent the drug from adhering to the bedding during bedtime. In addition, since the application amount of the drug is small, 150 g/m ² or less, even if the cosmetic product is used in a state where the mouth or nostril is covered, it is easy to breathe. According to these circumstances, the beauty product can be used for a long time such as bedtime.

In this type of beauty product, a drug containing at least one of silver oxide and butylcarbamate propynyl iodide and triol is used as a drug to be coated on the contact surface of the beauty product body , Can improve corrosion resistance.

Based on the above, the beauty product is a beauty product that can be used for a long time such as bedtime and has excellent antiseptic properties. Moreover, the beauty product can be used for a long time such as bedtime, and the coating amount of the drug is 20 g/m ² or more, so it can fully exert the effect of the drug contacting the face. Effects, such as moisturizing properties.

In addition, in the beauty product, the content of the triol in the drug is preferably 5 mass% to 90 mass%.

According to this structure, it is possible to further improve the corrosion resistance while maintaining excellent moisture retention.

In addition, in the beauty product, the triol is preferably glycerin.

According to this structure, it is possible to further improve the moisturizing properties while maintaining excellent anticorrosive properties.

In addition, in the cosmetic product, the agent preferably further contains a glycol.

According to this structure, it is possible to further improve the corrosion resistance while maintaining excellent moisture retention.

In addition, in the cosmetic product, the glycol is preferably at least one selected from the group consisting of propanediol, propylene glycol, butylene glycol, and dipropylene glycol.

According to this structure, it is possible to further improve the corrosion resistance while maintaining excellent moisture retention.

In addition, in the beauty product, the diol preferably contains two or more kinds.

According to this structure, it is possible to further improve the corrosion resistance while maintaining excellent moisture retention.

In addition, in the beauty product, the water content of the drug is preferably 50% by mass or less.

According to this structure, the corrosion resistance can be further improved. [Effects of the invention]

According to the present invention, it is possible to provide a beauty product that can be used for a long time such as bedtime and is excellent in corrosion resistance.

As described above, the inventors of the present invention found that by applying the drug to a smaller amount of 150 g/m ² or less, the drug can be applied to the contact surface in contact with the face. Use it for a long time. The inventors of the present invention conducted further studies, and as a result, found that in the case of such a small coating amount, the corrosion resistance may become insufficient in some cases. That is, it is considered that a cosmetic product that is permeated with a medicament containing cosmetic ingredients such as a moisturizer and is used in contact with the face like a sheet mask can exhibit sufficient antiseptic performance by making the medicament contain a preservative and increasing the amount of medicament applied. Sex. According to research conducted by the inventors of the present invention, such beauty products cannot sufficiently suppress the adhesion of the drug to the bedding during bedtime, and it is difficult to use them overnight. Furthermore, if the beauty product is used in a state covering the mouth or nostrils, it becomes difficult to breathe, and it is also difficult to use it overnight. Based on these circumstances, the inventors of the present invention discovered that the corrosion resistance can be improved by studying the composition of the drug instead of increasing the coating amount of the drug, and came up with the following invention.

The beauty product of the present invention includes: a beauty product body having a contact surface capable of contacting at least a part of the face; and a drug applied to the contact surface of the beauty product body. Regarding this beauty product, as described above, the drug is first applied to the contact surface that can come into contact with the face, that is, the inner surface of the beauty product body, so that the drug can be prevented from adhering to the bedding during bedtime. . The medicament is coated on the contact surface with a coating amount of 20 g/m ² to 150 g/m ^2. In this way, since the coating amount of the drug is less than 150 g/m ² , it is also possible to prevent the drug from adhering to the bedding during bedtime. In addition, since the application amount of the drug is small, 150 g/m ² or less, even if the cosmetic product is used in a state where the mouth or nostril is covered, it is easy to breathe. According to these circumstances, the beauty product can be used for a long time such as bedtime. On the other hand, since the coating amount of the drug is 20 g/m ² or more, the effects, such as moisturizing properties, etc., exerted by the contact of the drug with the face can be fully exhibited. According to these circumstances, the beauty product can be used for a long period of time such as bedtime, and furthermore can fully exhibit the effects of the agent contacting the face, such as moisturizing properties.

In this type of beauty product, a drug containing at least one of silver oxide and butylcarbamate propynyl iodide and triol is used as a drug to be coated on the contact surface of the beauty product body , Can improve corrosion resistance. Therefore, the beauty product is a beauty product that can be used for a long time such as bedtime and has excellent antiseptic properties.

Hereinafter, embodiments of the present invention will be described, but the present invention is not limited to these.

(First Embodiment) The beauty product 1 according to the first embodiment of the present invention will be described with reference to Figs. 1 to 4. This beauty product 1 can be worn at bedtime, etc., to obtain the effects exerted by the agent contacting the face, for example, the beauty effects such as moisturizing properties.

As described above, the beauty product 1 includes a beauty product body 11. In addition, the beauty product 1 includes a drug applied to the contact surface 11a of the beauty product body 11 that can come into contact with at least a part of the face. That is, the beauty product 1 includes a drug layer 40 containing the drug (see FIG. 3). In addition, the beauty product 1 may also include a fixing portion 30 for fixing the beauty product body 11. Examples of the fixing portion 30 include a fixing portion including a pair of holding portions 31 and the like.

In addition, Fig. 1 is a side view showing the beauty product 1 according to the first embodiment of the present invention. Fig. 2 is a front view showing the beauty product 1 shown in Fig. 1. Fig. 3 is an exploded perspective view showing the beauty product main body 11 included in the beauty product 1 shown in Fig. 1. Fig. 4 is a diagram schematically showing a situation when the beauty product 1 shown in Fig. 1 is worn. Fig. 1 is a side view showing a cross section that appears by cutting the beauty product 1 along the central straight line C (refer to Fig. 2 ).

Hereinafter, the direction connecting the pair of holding portions 31 (the left-right direction in FIG. 2) is referred to as the width direction, and the direction orthogonal to the width direction (the up-down direction in FIGS. 1 and 2) is referred to as the up-down direction.

As shown in FIG. 4, the beauty product body 11 included in the beauty product 1 is in contact with at least a part of the face. As shown in FIG. 3, the beauty product body 11 has a contact surface 11a capable of contacting at least a part of the face. Specifically, in this embodiment, as shown in FIG. 4, the contact surface which is in contact with at least a part of the face is provided so as to be able to contact at least the mouth and the nostril of the face. However, the present invention is not limited to this configuration, and the contact surface may be provided to be able to contact the eyes and their surroundings, or may be provided to be able to contact substantially the entire face of the face.

As shown in FIG. 3, the beauty product body 11 includes a fibrous body 10. The fibrous body 10 may include, for example, non-woven fabric, woven fabric, and the like. In this embodiment, the fibrous body 10 has a two-layer structure including an inner layer 10A and an outer layer 10B. The inner layer 10A is a layer on the side in contact with the face (skin), and the outer layer 10B is a layer on the side in contact with outside air. The inner layer 10A and the outer layer 10B may only overlap without being adhered to each other except for the welded portion 12A and the outer edge portion described later.

As the inner layer 10A, for example, a spunlace nonwoven fabric formed by a spunlace method or the like can be cited. In addition, as the spunlace nonwoven fabric, for example, spunlace split fiber composite nonwoven fabric and the like can be cited. More specifically, it can include 65% by mass of polyethylene terephthalate fibers and 35% by mass of polyamide fibers. The spunlace split fiber composite non-woven fabric and so on.

The beauty product 1 includes a medicament coated on the contact surface of the beauty product body 11. That is, the drug is held on the fibrous body 10. Specifically, the medicament is arranged such that when the beauty product 1 is fixed to the face and the contact surface 11a of the beauty product main body 11 contacts the face, the medicament contacts the face on the contact surface 11a. The drug is held by at least the inner layer 10A in the fibrous body 10. Specifically, the medicine is held by the inner layer 10A. More specifically, the medicine is provided on the inner surface of the inner layer 10A to form the medicine layer 40 (for example, the part indicated by the diagonal line in FIG. 3 ). In addition, the medicament may be impregnated in the inner layer 10A or attached to the inner surface of the inner layer 10A. For example, when the drug is impregnated in the inner layer 10A, not only the inner layer 10A but also the outer layer 10B may be impregnated with the drug. From the viewpoint of suppressing adhesion to bedding, it is preferable that the drug is impregnated in the inner layer 10A, and the drug is not impregnated in the outer layer 10B. Furthermore, the medicament may be in a liquid form or in a cream form, for example.

The drug is not particularly limited as long as it is a drug containing at least one of silver oxide and propynyl iodide of butylcarbamate and a triol. That is, the drug may be a drug that contains at least one of silver oxide and butylcarbamate propynyl iodide and a triol, and has a beneficial effect on the skin by contact with skin such as the face. .

The triol is not particularly limited, and examples include glycerin. In addition, the content of the triol relative to the drug is preferably 5 mass% to 90 mass%, more preferably 30 mass% to 70 mass%. If the content of the triol is too low, the moisture retention tends to decrease. In addition, if the content of the triol is too high, the content of the diol is relatively too low, and the corrosion resistance tends to decrease. Therefore, when the content of the triol is within the above range, it is possible to improve the corrosion resistance while maintaining excellent moisture retention.

The agent contains at least one of silver oxide and butylcarbamate propynyl iodide. As the preservative, it may also contain preservatives other than silver oxide and butylcarbamate propynyl iodide (other preservative). Silver oxide and propynyl iodide butylcarbamate have excellent resistance to mold and bacteria. The other preservatives are not particularly limited, and examples include alkyl parabens such as methyl paraben and propyl paraben, phenoxyethanol, and methylparaben (methylparaben). )Wait. The other preservatives can be used alone or in combination of two or more. In addition, the content of the preservative (the total content of silver oxide, propynyl butylcarbamate, and other preservatives) is preferably 0.1% by mass to 5% by mass relative to the drug. In addition, the total content of silver oxide and propynyl iodide butylcarbamate relative to the above-mentioned drug is preferably 0.2% by mass to 2% by mass. If these content rates are too low, there is a tendency that the corrosion resistance cannot be sufficiently exhibited. In addition, if these content rates are too high, the wearer tends to feel irritation when the beauty product is used in contact with human skin. In addition, the preservative may also contain pentasodium diethylenetriaminepentaacetic acid, phytic acid, and hydroxypropyl cyclodextrin.

The agent may also contain preservatives (silver oxide and propynyl iodide butyl carbamate, etc.) and components (other components) other than triol. Examples of other components include humectants other than glycols, glycols, and triols, whitening agents, astringents, skin protectants, skin nutrients, water, and the like.

The diol is not particularly limited, and examples thereof include butanediol such as propanediol, propylene glycol, and 1,3-butanediol, and dipropylene glycol. As the diol, it may be used alone or in combination of two or more kinds. That is, the diol is preferably at least one selected from the group consisting of propanediol, propylene glycol, butylene glycol, and dipropylene glycol. In addition, in the case where the diol is contained in the drug, its content relative to the drug is preferably 5 mass% to 90 mass%, and more preferably 5 mass% to 30 mass%. In addition, the medicament may not contain a diol, that is, the content of the diol may be substantially 0% by mass.

From the standpoint of improving antiseptic properties, the agent more preferably contains two or more of the diols. For example, in the case of containing two of the diols, the quality ratio of one diol to the other diol is preferably 1:1 to 1:6.

The moisturizer is a moisturizer other than dihydric alcohol and trihydric alcohol, and is not particularly limited. Examples of the moisturizer include hyaluronic acid such as collagen and hyaluronic acid fermentation broth, ceramide, and squalane. Among them, hyaluronic acid such as hyaluronic acid fermentation broth is preferred. In addition, the moisturizer may be used alone or in combination of two or more kinds. In addition, the moisturizer may also contain phenoxyethanol, disodium ethylenediaminetetraacetic acid dihydrogen dihydrate (EDTA-2Na), and the like.

The whitening agent is not particularly limited, and examples thereof include vitamin C derivatives, hydroquinone, and arbutin. In addition, the whitening agent may be used alone or in combination of two or more kinds.

The astringent is not particularly limited, and examples thereof include citric acid, alum, and ethanol. In addition, the astringent may be used alone or in combination of two or more kinds.

As described above, water may be included in the agent, but from the viewpoint of improving the antiseptic property, the content is preferably small. The water content is preferably 50% by mass or less, and more preferably 25% by mass or less. In addition, the agent may not contain water, that is, the water content may be substantially 0% by mass.

The coating amount of the medicament to the contact surface 11a is 20 g/m ² ～150 g/m ² , preferably 40 g/m ² ～120 g/m ² , more preferably 60 g/m ² ～ 100 g/m ² . If the coating amount is too small, there is a tendency that the effect exerted by the contact of the agent with the face, such as cosmetic effects such as moisturizing properties, etc., cannot be sufficiently achieved. In addition, if the coating amount is too large, there is a tendency that the drug cannot be sufficiently prevented from adhering to the bedding, and furthermore, when the beauty product 1 is used in a state covering the mouth or nostrils, it tends to be difficult to breathe. Therefore, if the coating amount is within the above range, the beauty product 1 can be used for a long time such as bedtime, and the effect of the contact of the drug with the face can be fully exhibited. For example, moisture retention and so on.

The outer layer 10B is arranged outside the inner layer 10A. Examples of the outer layer 10B include non-woven fabrics, and more specifically, spun-bonded non-woven fabrics formed by a spunbond method. In addition, as the spunbonded nonwoven fabric, for example, a spunbonded nonwoven fabric including polypropylene and the like can be cited. In addition, the outer layer 10B has hydrophobicity. Specifically, the outer layer 10B preferably has hydrophobicity to the extent that when water is dripped onto the surface of the outer layer 10B, the dripped water is not absorbed. The outer layer 10B more preferably has hydrophobicity, so-called water repellency, to such a degree that when water is dropped onto the surface of the outer layer 10B, the dropped water is bounced off the surface of the outer layer 10B to form water droplets.

The pressure loss of the outer layer 10B is preferably smaller than the pressure loss of the inner layer 10A. The pressure loss corresponds to the ventilation resistance. The pressure loss of the inner layer 10A is preferably 1.0 mmH ₂ O/cm ² to 2.5 mmH ₂ O/cm ² . The pressure loss of the outer layer 10B is preferably greater than 0 mmH ₂ O/cm ² and 0.5 mmH ₂ O/cm ² or less. The pressure loss of the beauty product body 11 is preferably 1.3 mmH ₂ O/cm ² to 3.1 mmH ₂ O/cm ² .

In addition, the said pressure loss can be measured as follows, for example. Mount the humidity-conditioned sample on a cylindrical sample holder with a diameter of 2.5 cm, and use a pump to pump at a flow rate of 8 L/min. The pressure loss (mmH _{2 O) at this time was measured, and the value (mmH 2} O/cm ² ) obtained by dividing by the measured area was used as the final result. This is a measurement carried out in accordance with the currently obsolete specification test number MIL-M-36954C.

The bending hardness of the inner layer 10A is preferably smaller than the bending hardness of the outer layer 10B. The bending hardness of the outer layer 10B is preferably 0.08 g/cm or more. The bending hardness of the inner layer 10A is preferably less than 0.08 g/cm. The bending hardness of the beauty product body 11 is preferably 0.50 g/cm or less.

In addition, the said bending hardness can be measured as follows, for example. First, each sheet of the inner layer 10A and the outer layer 10B constituting the beauty product 1 is cut into a length of 150 mm and a width of 50 mm. This cut was used as a sample. Furthermore, the sample may be taken from the beauty product 1 or from the respective sheets constituting the inner layer 10A and the outer layer 10B of the beauty product 1. Furthermore, in the case of measuring the bending hardness of the beauty product body 11, in a state where each sample is overlapped, for example, automatic pure bending such as KESFB-2AUTO-A (manufactured by Katohtek Co., Ltd.) is used. The testing machine gives a certain curvature while measuring the bending moment per 1 cm width in the longitudinal direction. In addition, in the case of measuring the bending hardness of each layer of the inner layer 10A and the outer layer 10B, each sample is used to measure the bending hardness of the beauty product body 11 by the same method as that of each 1 cm in the longitudinal direction. Wide bending moment. Then, by calculating the average slope (dM/dK) of the bending moment M when the curvature K is 0.5 cm ^-1 to 1.5 cm ^{-1, the bending hardness can be measured.}

Next, the shape of the beauty product main body 11 will be described with reference to FIGS. 1, 2 and 4. The beauty product body 11 has a central covering part 12, a side covering part 16, an inner covering part 20, and an outer covering part 22. As shown in FIG. 2, the beauty product body 11 has a center line C (refer to FIG. 2) that passes through the center of the beauty product body 11 in the width direction and extends in the vertical direction, which is symmetrical in the width direction. shape.

The central covering part 12 is a part covering the parts around the mouth and nostrils in the face. Specifically, the central covering portion 12 includes a nasal covering portion 13 and a covering portion 14 around the mouth. The nasal covering part 13 is a part covering the nose. The mouth periphery covering part 14 is a part covering the mouth periphery. The mouth-peripheral covering part 14 is connected to the underside of the nasal covering part 13.

As shown in FIG. 1, the central covering portion 12 has a state where the beauty product body 11 is bent along the central straight line C (refer to FIG. 2), and protrudes in a direction away from the holding portion 31 Curved shape in a way. At the edge portion of the curved portion (in the central covering portion 12, the end portion located on the side away from the holding portion 31 in the state where the beauty product body 11 is bent along the central straight line C ( The end portion on the left side of FIG. 1)) is formed with a welded portion 12A.

The side covering portion 16 is connected to the side of the central covering portion 12. The side covering part 16 covers the area around the cheeks or the chin in the covering face. The holding portion 31 is connected (welded) to the side covering portion 16.

The inner covering portion 20 is connected to the side of the central covering portion 12 and above the side covering portion 16. The inner covering part 20 is a part that covers the part between the eyes and the cheeks (the part under the eyes) of the face when the beauty product body 11 is held in a state of covering the mouth and nostrils by the fixing part 30. In the present embodiment, the upper edge portion of the inner covering portion 20 in the vertical direction has a concave shape so as to protrude downward.

The outer covering portion 22 is arranged on the outer side of the inner covering portion 20 in the width direction, and is arranged on the upper side of the inner covering portion 20 in the vertical direction. The outer covering part 22 is a part that covers the corners of the eyes and the vicinity thereof when the beauty product body 11 is held in a state of covering the mouth and nostrils by the fixing part 30. The upper edge portion of the outer covering portion 22 in the vertical direction has a shape that is curved so as to protrude upward. The end portion on the inner side in the width direction of the upper edge portion of the outer covering portion 22 in the vertical direction has a shape that is curved so as to protrude downward. As shown in FIG. 1, the outer covering portion 22 has a shape protruding upward from a straight line HL, which is perpendicular to the reference straight line L that connects the upper end and the lower end of the welded portion 12A and passes through the vertical direction. The lower end portion of the upper edge portion of the inner covering portion 20. The protruding dimension h of the upper edge portion of the outer covering portion 22 from the straight line HL upward (the straight line HH perpendicular to the reference straight line L and passing through the upper end portion of the upper edge portion of the outer covering portion 22 is compared The distance h) of the straight line HL is preferably set to 5 mm or more, more preferably set to 5 mm or more and 30 mm or less, further preferably set to 15 mm or more and 27 mm or less, particularly preferably set to 18 mm or more And below 24 mm. Hereinafter, in this embodiment, an example in which the protrusion size h is set to 19 mm will be described.

The pair of holding parts 31 constituting the fixing part 30 is a member that fixes the beauty product main body 11 so as to be in contact with the face. The holding portion 31 is connected to the side portion of the beauty product body 11 in a state of covering the mouth and nostrils. The pair of holding parts 31 hold the beauty product body 11 in a state where the beauty product body 11 covers the mouth and nostrils. As the holding portion 31, for example, ear straps and the like can be cited. Each end 32 of the ear hanging part is welded to the side covering part 16 of the beauty product body 11. In the present embodiment, as a pair of the holding portions 31, ear-hanging portions are used, respectively. In addition, the end portion 32 (the welded portion between each end portion 32 and the beauty product body 11) has a rectangular shape.

As described above, according to the beauty product 1 of this embodiment, since the drug is applied to the contact surface 11a of the beauty product body 11, even if the beauty product 1 is worn during bedtime In this case, it is also possible to prevent the agent from adhering to the bedding during bedtime. Furthermore, since the application amount of the drug is reduced to 150 g/m ² or less, it is also possible to prevent the drug from adhering to the bedding during bedtime. In addition, since the application amount of the drug is reduced to 150 g/m ² or less, the ease of breathing can also be ensured. According to these circumstances, the beauty product 1 can be used for a long period of time such as bedtime. That is, the beauty product 1 uses the fixing portion 30 to fix the beauty product body 11 coated with the drug on the face before going to bed, so that it can be used for a long period of time such as bedtime. The state where the contact surface 11a of the beauty product body 11 is in contact with the face is maintained.

In this beauty product 1, a drug containing at least one of silver oxide and butylcarbamate propynyl iodide and triol is used as a drug that is applied to the contact surface 11a of the beauty product body 11. The medicament can improve the corrosion resistance.

Based on the above, the beauty product 1 is a beauty product that can be used for a long time such as bedtime and is excellent in corrosion resistance. Furthermore, since the coating amount of the drug is 20 g/m ² or more, the effects, such as moisturizing properties, etc., exerted by the contact of the drug with the face can be sufficiently exhibited. That is, the feeling of use such as a mask for makeup can be obtained, and the beauty effect of the face can be obtained. In addition, by using the beauty product 1, the drug can be continuously supplied to the face from the beauty product body 11 for a long bedtime, so that a further beauty effect can be obtained.

The beauty product 1 can be preferably used in a bedtime state even when the secretion amount of growth hormone is large and a high beauty effect can be obtained, for example, between 22:00 and 2:00. Therefore, according to the beauty product 1 of this embodiment, a higher beauty effect can be achieved.

In the beauty product 1 of this embodiment, when a pair of the holding parts 31 are hung on the ears (when the beauty product body 11 is held by the pair of holding parts 31 in a state covering the mouth and nostrils) , The part of the drug layer 40 located on the inner surface of the inner covering part 20 is in contact with the part under the eye, and the part of the drug layer 40 provided on the inner surface of the outer covering part 22 and the corner of the eye and Contact with nearby parts. Therefore, it is possible to obtain a cosmetic effect in the vicinity of the eye, including the corners of the eye, which requires high cosmetics. Therefore, by wearing the beauty product 1, the beauty effect of the face is improved.

In the beauty product 1 of the present embodiment, the edge portion on the upper side of the outer covering portion 22 has a shape that is curved so as to protrude upward. Therefore, compared with the case where a corner portion is formed on the edge portion on the upper side of the outer covering portion 22, it is possible to prevent fingers or the like from being caught on the outer covering portion 22. Therefore, peeling (rolling up) of the outer coating portion 22 can be suppressed. In addition, the usability of the beauty product 1 is improved.

Furthermore, in the beauty product 1 of this embodiment, the said outer coating part 22 has the shape which protrudes 5 mm or more from the said straight line HL upwards. Therefore, the portion of the drug layer 40 located on the inner surface of the outer coating portion 22 effectively contacts the corner of the eye and its vicinity. Therefore, the drug can be preferably supplied to the corner of the eye and its vicinity. Therefore, by wearing the beauty product 1, the beauty effect of the face is further improved.

In the beauty product 1 of the present embodiment, the inner end in the width direction of the upper edge portion of the outer covering portion 22 in the vertical direction has a shape that is curved so as to protrude downward. Therefore, the parts of the drug layer 40 located on the inner surfaces of the inner coating portion 20 and the outer coating portion 22 have improved adhesion to the eye. Therefore, the medicine can be preferably supplied to the eye. Therefore, by wearing the beauty product 1, the beauty effect of the face is further improved.

In the beauty product 1 of the present embodiment, the upper edge portion of the inner covering portion 20 has a shape recessed in a concave shape so as to protrude downward. Therefore, the adhesiveness of the part located on the inner surface of the inner coating portion 20 in the drug layer 40 to the eye is further improved.

In the beauty product 1, it is preferable that the outer layer 10B has hydrophobicity. In the case of such a beauty product 1, the evaporation of the drug can be suppressed. Therefore, the cosmetic effect and the feeling of use brought by the drug layer 40 last for a long time. Therefore, the beauty effect can be obtained for a long time such as during bedtime.

In the beauty product 1, the pressure loss of the outer layer 10B is preferably smaller than the pressure loss of the inner layer 10A. In the case of such a beauty product 1, when the beauty product body 11 becomes negative pressure due to breathing during the wearing of the beauty product 1, the inner layer 10A is deformed toward the skin and comes into contact with the skin , So the beauty effect is improved. In addition, deformation of the outer layer 10B inward during breathing can be suppressed. Therefore, a space is formed between the outer layer 10B and the inner layer 10A during breathing, so that ease of breathing can be ensured.

In the beauty product 1, it is preferable that the bending hardness of the inner layer 10A is smaller than the bending hardness of the outer layer 10B. In the case of such a beauty product 1, the deformation of the inner layer 10A to the skin during breathing can be promoted, and therefore the beauty effect can be further improved.

In this embodiment, the example in which the beauty product body 11 has a two-layer structure of the inner layer 10A and the outer layer 10B has been described, but the present invention is not limited to this. The beauty product body in the beauty product of the present invention may include a piece of fibrous body (for example, non-woven fabric, etc.), and may also include two fibrous bodies as in the first embodiment, or may include more than three fibrous bodies. Hereinafter, in the second embodiment, a beauty product in which the beauty product body includes three fiber bodies will be described.

(Second Embodiment) Next, referring to Fig. 5, the beauty product 1 according to the second embodiment of the present invention will be described. In addition, in the second embodiment, only the parts that are different from the first embodiment will be described, and the description of the same structure, action, and effect as in the first embodiment will be omitted.

In the beauty product 1 of this embodiment, as shown in FIG. 5, the beauty product body 11 includes the fiber body 10. The fibrous body 10 has a three-layer structure including an inner layer 10A, an outer layer 10B, and an intermediate layer 10C. The intermediate layer 10C is disposed between the inner layer 10A and the outer layer 10B. The respective layers 10A to 10C overlap, not adhere to each other, except for the welded portion 12A and the outer edge portion. Furthermore, FIG. 5 is an exploded perspective view showing the beauty product main body 11 included in the beauty product 1 according to the second embodiment of the present invention.

As the intermediate layer 10C, for example, an air-through nonwoven fabric formed by an air-through method or the like can be cited. Moreover, as the said hot-air nonwoven fabric, the hot-air nonwoven fabric containing only polypropylene etc. is mentioned, for example.

In the beauty product 1, when the drug is impregnated in the inner layer 10A, not only the inner layer 10A but also the intermediate layer 10C may be impregnated with the drug, The agent may be impregnated in the outer layer 10B. From the viewpoint of inhibiting adhesion to bedding, it is preferable not to impregnate the drug in the outer layer 10B and to impregnate the drug in the inner layer 10A and the intermediate layer 10C, more preferably only The drug is impregnated in the inner layer 10A.

In the beauty product 1, it is preferable that the pressure loss of the middle layer 10C is smaller than the pressure loss of the outer layer 10B, and the pressure loss of the outer layer 10B is smaller than the pressure loss of the inner layer 10A. In the case of such a beauty product 1, the intermediate layer 10C can suppress the deformation of the outer layer 10B to the inner side while hardly obstructing the ventilation from the outer layer 10B to the inner layer 10A during breathing. Therefore, a space is more reliably formed between the outer layer 10B and the inner layer 10A during breathing, thereby further ensuring the ease of breathing. The pressure loss of the intermediate layer 10C is greater than 0 mmH ₂ O/cm ² and less than 0.3 mmH ₂ O/cm ² .

(Third Embodiment) Next, the beauty product 1 of the third embodiment of the present invention will be described with reference to Figs. 6 to 8. In addition, in the third embodiment, only the parts that are different from the first embodiment will be described, and the description of the same structure, action, and effect as in the first embodiment will be omitted. Furthermore, FIG. 6 is a side view showing the beauty product 1 according to the third embodiment of the present invention. Fig. 7 is a front view showing the beauty product 1 shown in Fig. 6. Fig. 8 is a diagram schematically showing a situation when the beauty product 1 shown in Fig. 6 is worn.

In the beauty product 1 of this embodiment, the shape of the beauty product body 11 of the third embodiment is different from the shape of the beauty product body 11 of the first embodiment. As shown in FIG. 6, the shape of the beauty product main body 11 of the third embodiment, particularly the shapes of the central covering portion 12 and the inner covering portion 20, are different from the shapes of the central covering portion 12 and the inner covering portion 20 of the first embodiment.

The boundary between the nose covering part 13 and the mouth periphery covering part 14 in the central covering part 12 has a state in which the beauty product body 11 is bent along the central straight line C from the nose covering part 13 to the fixing part 30 (ear hanging part) The shape of the side recessed. Therefore, when a pair of ear-hanging parts are hung on the ears, the boundary between the nasal covering part 13 and the mouth-peripheral covering part 14 is likely to be in close contact with the part below the nose. Therefore, the cosmetic effect of the area under the nose is improved.

The inner covering portion 20 is formed in a substantially linear shape. In the present embodiment, the protrusion dimension h of the outer covering portion 22 upward from the straight line HL is set to 22.5 mm.

Furthermore, it should be considered that the said embodiment disclosed this time is an illustration in all respects, and does not restrict|limit. The scope of the present invention is shown by the scope of the patent application rather than the description of the embodiment, and further includes the meaning equivalent to the scope of the patent application and all changes within the scope.

For example, in the third embodiment, the shape of the upper edge portion of the inner covering portion 20 may be set to be the same as the shape of the first embodiment.

The pair of holding parts 31 are not limited to ear-hanging parts. For example, the holding portion 31 may be an adhesive portion that can be attached to the face, and the adhesive portion may have a structure that protrudes outward from the side of the beauty product body 11 in the width direction, or may constitute the beauty product body 11 part of the structure.

For example, in the present invention, the beauty product for bedtime may further include members other than the beauty product body and the fixing part.

The beauty product of the present invention can be used for a long time such as bedtime, but this does not exclude that it can also be used during periods other than bedtime. For example, the beauty product may be worn at a time earlier than bedtime, and the beauty product may be worn before going to bed. In addition, it is also possible to wear the beauty product to bed, and to spend time wearing the beauty product after waking up.

Hereinafter, the present invention will be explained more specifically with examples, but the scope of the present invention is not limited to these. [Example]

In this example, the antiseptic property of the non-woven fabric constituting the main body of the beauty product included in the beauty product was investigated.

[Example 1 to Example 3, and Comparative Example 1 to Comparative Example 3] In this example, each component contained in the medicine used will be described.

(Triol) Glycerin: Glycerin (concentrated glycerin for cosmetics manufactured by Sakamoto Pharmaceutical Co., Ltd.) Water: Refined water (Japanese bureau grade) (Diol) DPG: Dipropylene glycol (SKC Co., Ltd ) DPG manufactured) BG: 1,3-Butanediol (1,3-BG manufactured by Daicel Co., Ltd.) (Humectant: humectant other than glycol and triol) Fermented hyaluronic acid Acid-K: Hyaluronic acid fermentation broth 99.4% by mass, phenoxyethanol 0.5% by mass, and ethylenediaminetetraacetic acid dihydrogen disodium dihydrate (EDTA-2Na) 0.1% by mass mixed liquid (Tecnobao (Fermented hyaluronic acid-K manufactured by Technoble Co., Ltd.) (preservative) Jewel Silver: 0.052% by mass of silver oxide, 94.698% by mass of water, 5.0% by mass of pentasodium diethylenetriaminepentaacetic acid, and A mixture of phytic acid 0.25% by mass (jewel silver manufactured by JTS Co., Ltd.) Glycacil2000: 6% by mass of butylcarbamate propynyl iodide, 47% by mass of hydroxypropyl cyclodextrin, and 47% by mass of water Mixture (Glycacil2000 manufactured by Lonza China) Mekkins-M: Methyl paraben (Mekkins-M manufactured by Ueno Pharmaceutical Co., Ltd.) to become as shown in Table 1 The composition (mass%) of the ingredients are mixed. By proceeding in the manner described, a drug can be obtained. Coat the obtained agent on a 5 cm square non-woven fabric (including 65% by mass of polyethylene terephthalate fiber and 35% by mass of polyamide fiber) so that the coating amount becomes 60 g/m ² Spunlace split fiber composite non-woven fabric, D0822 manufactured by Kuraray Kuraflex Co., Ltd.). By proceeding in the manner described, a sample can be obtained. The samples obtained in this manner were evaluated by the following corrosion resistance test.

[Corrosion resistance (initial product)] The sample obtained shortly after the method described above, that is, the initial product, was used. The surface of the sample (initial product) coated with the drug was inoculated with 10 to the 7th power of Candida albicans (C. albicans), Aspergillus brasiliensis (A. brasiliensis), and Penicillium citrinum (P .citrinum). After that, in an environment with a temperature of 20° C. to 30° C. and a relative humidity of 70% RH to 100% RH, the number of bacteria after culturing for 4 weeks was measured. As a result, when the number of bacteria inoculated was reduced by more than two levels compared with the initial inoculation, it was evaluated as "≦1%". In addition, when the number of inoculated bacteria is reduced by more than one level and less than two levels from the initial inoculation, the evaluation is "≦10%". In addition, when the amount of reduction is less than one level compared with the initial inoculated bacterial count, and the growth of the bacteria cannot be confirmed, it is evaluated as "≦100%". In addition, when the amount of reduction is less than one level compared with the initial number of inoculated bacteria, and the growth of bacteria can be confirmed, it is evaluated as "100%≦". In addition, if it is "≦1%", it can be evaluated as high corrosion resistance (anticorrosion effect), and if it is "≦10%", it can be evaluated as having corrosion resistance (anticorrosion effect). If it is "≦100%", the corrosion resistance (corrosion effect) is lower than "≦10%", but it can be evaluated as having corrosion resistance (corrosion effect), and if it is "100%≦", it is evaluated as having no corrosion resistance ( Anti-corrosion effect).

[Corrosion resistance (products that change over time)] The sample obtained as described above was left in an environment with a temperature of 50° C. and a relative humidity of 30% RH for one month, that is, a sample that changes with time. The evaluation was performed in the same manner as the above-mentioned "corrosion resistance (initial product)" except that a product that changes with time was used instead of the initial product. In addition, this time-varying product corresponds to a sample 1.5 years after manufacture.

Table 1 shows the evaluation results of these anticorrosive properties.

[Table 1] Example Comparative example 1 2 3 1 2 3 Composition (mass%) Triol glycerin 68 68 68 68 68 40 water 30.9 20.9 10.9 31.5 31.2 59.5 Glycol DPG - - 10 - - - BG - 10 10 - - - moisturizer Fermented Hyaluronic Acid-K 0.5 0.5 0.5 0.5 0.5 0.5 preservative Gem silver 0.3 0.3 0.3 - - - Glycacil2000 0.3 0.3 0.3 - - - Mekins-M - - - - 0.3 - total 100 100 100 100 100 100 Evaluation Corrosion resistance Initial product ≦10% ≦1% ≦1% 100%≦ 100%≦ 100%≦ Changes over time ≦10% ≦1% ≦1% 100%≦ 100%≦ 100%≦

It can be seen from Table 1 that the case of using a drug containing at least one of silver oxide and butylcarbamate iodide propynyl ester and a triol (Example 1 to Example 3) and the case (comparison) Compared with Example 1 to Comparative Example 3), the corrosion resistance is higher.

1: beauty products 10: Fibrous body 10A: inner layer 10B: Outer layer 10C: Middle layer 11: Beauty products body 11a: contact surface 12: Central cover 12A: Welding part 13: Nasal covering 14: Cover around the mouth 16: side covering 20: Inside cover 22: Outer cover 30: fixed part 31: Holding part 32: end 40: Pharmacy layer C: Central straight line h: Protruding size HH, HL: straight line L: Reference line

Fig. 1 is a side view showing a beauty product according to a first embodiment of the present invention. Fig. 2 is a front view showing the beauty product shown in Fig. 1. Fig. 3 is an exploded perspective view showing a beauty product main body included in the beauty product shown in Fig. 1. Fig. 4 is a diagram schematically showing a situation when the beauty product shown in Fig. 1 is worn. Fig. 5 is an exploded perspective view showing the beauty product main body included in the beauty product according to the second embodiment of the present invention. Fig. 6 is a side view showing a cosmetic product according to a third embodiment of the present invention. Fig. 7 is a front view showing the beauty product shown in Fig. 6. Fig. 8 is a diagram schematically showing a situation when the beauty product shown in Fig. 6 is worn.

10: Fibrous body

10A: inner layer

10B: Outer layer

11: Beauty products body

11a: contact surface

40: Pharmacy layer

Claims (7)

A cosmetic product, which is characterized by comprising: a cosmetic product body having a contact surface capable of contacting at least a part of the face; and a medicament applied to the contact at a coating amount of ^{20 g/m 2} to 150 g/m ² In the above, the agent includes at least one of silver oxide and propynyl iodide butyl carbamate, and a triol. The beauty product according to claim 1, wherein the content of the triol in the medicine is 5 mass% to 90 mass%. The beauty product according to claim 1 or claim 2, wherein the triol is glycerin. The cosmetic product according to any one of claim 1 to claim 3, wherein the medicament further comprises a glycol. The beauty product according to claim 4, wherein the glycol is at least one selected from the group consisting of propanediol, propylene glycol, butylene glycol, and dipropylene glycol. The beauty product according to claim 4 or claim 5, wherein the diol contains two or more kinds. The beauty product according to any one of claims 1 to 6, wherein the water content of the medicine is 50% by mass or less.

Images